Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance

Andrea A. Zachary, Lloyd E. Ratner, Julie A. Graziani, Donna P. Lucas, Nancy L. Delaney, Mary S. Leffell

Research output: Contribution to journalArticle

Abstract

Until recently, the nature of humoral sensitization to HLA has been characterized by data from lymphocyte-based assays, predominantly cytotoxicity tests. We have examined the characteristics, determined by enzyme-linked immunosorbent assay (ELISA), of sera from 191 subjects known to have produced HLA-specific antibody. We found that ELISA detected higher frequencies compared with cytotoxicity of many (74.5%), but not all, HLA-specific antibodies; in many cases (42.6%) the frequencies of these antibodies were higher than predicted from population frequencies whereas some antibodies (23.4%) occurred with lower than expected frequencies. Some of the increase in frequencies can be accounted for by crossreactivity, i.e., sensitization to epitopes shared among two or more allelic products. The presence of epitopes shared between a recipient's antigen and a mismatched antigen in a donor also tended to narrow the specificity of antibody produced. However the data also indicate differences in immunogenicity among different antigens suggesting that crossreactive group matching would be beneficial in some but not all cases. Finally, we present case studies to illustrate the value of ELISA in predicting humoral rejection episodes and in monitoring the efficacy of rejection therapies.

Original languageEnglish (US)
Pages (from-to)236-246
Number of pages11
JournalHuman Immunology
Volume62
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Enzyme-Linked Immunosorbent Assay
Antigens
Antibodies
Epitopes
Antibody Specificity
Lymphocytes
Serum
Population
Therapeutics

Keywords

  • CREG
  • ELISA
  • HLA antibody
  • Immunogenicity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Zachary, A. A., Ratner, L. E., Graziani, J. A., Lucas, D. P., Delaney, N. L., & Leffell, M. S. (2001). Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Human Immunology, 62(3), 236-246. https://doi.org/10.1016/S0198-8859(00)00253-6

Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets : II. Clinical relevance. / Zachary, Andrea A.; Ratner, Lloyd E.; Graziani, Julie A.; Lucas, Donna P.; Delaney, Nancy L.; Leffell, Mary S.

In: Human Immunology, Vol. 62, No. 3, 2001, p. 236-246.

Research output: Contribution to journalArticle

Zachary, Andrea A. ; Ratner, Lloyd E. ; Graziani, Julie A. ; Lucas, Donna P. ; Delaney, Nancy L. ; Leffell, Mary S. / Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets : II. Clinical relevance. In: Human Immunology. 2001 ; Vol. 62, No. 3. pp. 236-246.
@article{f39a73dff3c34e66982b68b5a5043f6d,
title = "Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance",
abstract = "Until recently, the nature of humoral sensitization to HLA has been characterized by data from lymphocyte-based assays, predominantly cytotoxicity tests. We have examined the characteristics, determined by enzyme-linked immunosorbent assay (ELISA), of sera from 191 subjects known to have produced HLA-specific antibody. We found that ELISA detected higher frequencies compared with cytotoxicity of many (74.5{\%}), but not all, HLA-specific antibodies; in many cases (42.6{\%}) the frequencies of these antibodies were higher than predicted from population frequencies whereas some antibodies (23.4{\%}) occurred with lower than expected frequencies. Some of the increase in frequencies can be accounted for by crossreactivity, i.e., sensitization to epitopes shared among two or more allelic products. The presence of epitopes shared between a recipient's antigen and a mismatched antigen in a donor also tended to narrow the specificity of antibody produced. However the data also indicate differences in immunogenicity among different antigens suggesting that crossreactive group matching would be beneficial in some but not all cases. Finally, we present case studies to illustrate the value of ELISA in predicting humoral rejection episodes and in monitoring the efficacy of rejection therapies.",
keywords = "CREG, ELISA, HLA antibody, Immunogenicity",
author = "Zachary, {Andrea A.} and Ratner, {Lloyd E.} and Graziani, {Julie A.} and Lucas, {Donna P.} and Delaney, {Nancy L.} and Leffell, {Mary S.}",
year = "2001",
doi = "10.1016/S0198-8859(00)00253-6",
language = "English (US)",
volume = "62",
pages = "236--246",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets

T2 - II. Clinical relevance

AU - Zachary, Andrea A.

AU - Ratner, Lloyd E.

AU - Graziani, Julie A.

AU - Lucas, Donna P.

AU - Delaney, Nancy L.

AU - Leffell, Mary S.

PY - 2001

Y1 - 2001

N2 - Until recently, the nature of humoral sensitization to HLA has been characterized by data from lymphocyte-based assays, predominantly cytotoxicity tests. We have examined the characteristics, determined by enzyme-linked immunosorbent assay (ELISA), of sera from 191 subjects known to have produced HLA-specific antibody. We found that ELISA detected higher frequencies compared with cytotoxicity of many (74.5%), but not all, HLA-specific antibodies; in many cases (42.6%) the frequencies of these antibodies were higher than predicted from population frequencies whereas some antibodies (23.4%) occurred with lower than expected frequencies. Some of the increase in frequencies can be accounted for by crossreactivity, i.e., sensitization to epitopes shared among two or more allelic products. The presence of epitopes shared between a recipient's antigen and a mismatched antigen in a donor also tended to narrow the specificity of antibody produced. However the data also indicate differences in immunogenicity among different antigens suggesting that crossreactive group matching would be beneficial in some but not all cases. Finally, we present case studies to illustrate the value of ELISA in predicting humoral rejection episodes and in monitoring the efficacy of rejection therapies.

AB - Until recently, the nature of humoral sensitization to HLA has been characterized by data from lymphocyte-based assays, predominantly cytotoxicity tests. We have examined the characteristics, determined by enzyme-linked immunosorbent assay (ELISA), of sera from 191 subjects known to have produced HLA-specific antibody. We found that ELISA detected higher frequencies compared with cytotoxicity of many (74.5%), but not all, HLA-specific antibodies; in many cases (42.6%) the frequencies of these antibodies were higher than predicted from population frequencies whereas some antibodies (23.4%) occurred with lower than expected frequencies. Some of the increase in frequencies can be accounted for by crossreactivity, i.e., sensitization to epitopes shared among two or more allelic products. The presence of epitopes shared between a recipient's antigen and a mismatched antigen in a donor also tended to narrow the specificity of antibody produced. However the data also indicate differences in immunogenicity among different antigens suggesting that crossreactive group matching would be beneficial in some but not all cases. Finally, we present case studies to illustrate the value of ELISA in predicting humoral rejection episodes and in monitoring the efficacy of rejection therapies.

KW - CREG

KW - ELISA

KW - HLA antibody

KW - Immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=0035082356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035082356&partnerID=8YFLogxK

U2 - 10.1016/S0198-8859(00)00253-6

DO - 10.1016/S0198-8859(00)00253-6

M3 - Article

C2 - 11250041

AN - SCOPUS:0035082356

VL - 62

SP - 236

EP - 246

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 3

ER -